Study of two drugs for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two new drugs, PM8002 and PM1009, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced liver cancer that cannot be removed with surgery or has spread.
- You have not had any prior treatment for this stage of liver cancer.
- Your liver function is good enough (Child-Pugh score of 7 or less).
- You can take care of yourself (ECOG score 0 or 1).
- You have at least one measurable tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial tests a combination of three drugs (TPST-1120, atezolizumab, and bevacizumab) for people with advanced liver cancer that hasn't been treated before. The goal is to see if adding this new drug to the standard immunotherapy and targeted therapy helps shrink or control the cancer better.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus targeted proton radiation for liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors and improve outcomes for people with intermediate or advanced stage liver cancer.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.